Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Major European Research Project to Focus on Detection and Prevention of Rheumatoid Arthritis

By BiotechDaily International staff writers
Posted on 14 Aug 2013
The European Union has agreed to fund a multimillion euro research project aimed at detection and prevention of rheumatoid arthritis in individuals who do not yet have symptoms of the disease.

Funding for the first four years of the EuroTEAM (Towards Early diagnosis and biomarker validation in Arthritis Management) project will be more than 5.7 million euros. These funds will underwrite the research efforts of 13 academic partners from six European countries - the United Kingdom, the Netherlands, Sweden, Switzerland, Germany, and Austria, as well as three industry partners, from Germany, the Netherlands, and Iceland.

The biotech company ORGENTEC Diagnostika (Mainz, Germany), which will head up the search for biomarkers in the blood, will be a major player on EuroTEAM. ORGENTEC is a global leader in development, production, and marketing of test systems for laboratory diagnostics. The company offers numerous highly specific ELISA tests, immunoblots, and kits for immunofluorescence assays. Its point of care test "rheumachec" was the first rapid test for diagnosing rheumatoid arthritis.

In the case of a chronic inflammatory disease such as rheumatoid arthritis, the goal is prevention. Development of preventive strategies and therapies requires (1) identification of biomarkers that can be used to predict an individual's risk of developing the disease, and (2) identification and characterization of modifiable disease mechanisms that can be manipulated in the early phases of disease.

The key objective of the TEAM consortium is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to rheumatoid arthritis. The plan is to achieve this by developing a collaborative, integrated program of work that will link academic researchers with key SMEs (small and medium sized enterprises) involved in biomarker development to produce a personalized predictive biomarker profile for patients destined to develop rheumatoid arthritis. Ultimately, the project will directly involve other medical specialists and patients.

Related Links:
ORGENTEC Diagnostika



view channel
Image: A new catalyst that improved the sensitivity of the standard PSA ELISA test by about 110-fold was made of palladium nanocubes coated with iridium (Photo courtesy of Dr. Xiaohu Xia, Michigan Technological University).

Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.